الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

tris pharma inc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg in 5 ml - morphine sulfate oral solution 2 mg/ml is indicated for the management of: - adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2 ) ], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. have not provided adequate analgesia, or are not expected to provide adequate analgesia. pediatric use information is approved for hikma pharmaceutic

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

specgx llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg in 1 ml - morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. have not provided adequate analgesia, or are not expected to provide adequate analgesia. pediatric use information is approved for hikma pharmaceuticals usa inc.’s morphine sulfate oral solution. however, due to hikma pharmaceuticals usa inc.’s marketing exclusivity rights, this drug product is not labeled with that information. morphine

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

precision dose inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg in 5 ml - morphine sulfate oral solution 2 mg/ml and 4 mg/ml is indicated for the management of - adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. - pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. morphine sulfate oral solution is contraindic

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

pai holdings, llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 100 mg in 5 ml - morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. morphine sulfate oral solution is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.4) ]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7) ]. - concurrent use of monoamine oxidase inhibitors (maois) or use of maois

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - buprenorphine (unii: 40d3scr4gz) (buprenorphine - unii:40d3scr4gz) - buprenorphine transdermal system is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. l imitations of use - because of the risks of addiction, abuse and misuse with opioids, even at recommended doses, and because of the greater risk of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve buprenorphine transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic buprenorphine transdermal system is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the

كندا - الفرنسية - Health Canada

mylan pharmaceuticals ulc - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 2mg; 0.5mg - buprénorphine (chlorhydrate de buprénorphine) 2mg; naloxone (chlorhydrate dihydraté de naloxone) 0.5mg - opiate partial agonists

كندا - الفرنسية - Health Canada

mylan pharmaceuticals ulc - buprénorphine (chlorhydrate de buprénorphine); naloxone (chlorhydrate dihydraté de naloxone) - comprimé - 8mg; 2mg - buprénorphine (chlorhydrate de buprénorphine) 8mg; naloxone (chlorhydrate dihydraté de naloxone) 2mg - opiate partial agonists

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 10 mg/ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 100 mg/5ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 20 mg/ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia